Funding for this research was provided by:
National Institute of Child Health and Human Development (U54-HD086984 (Sub-Project ID#8064))
National Institute on Deafness and Other Communication Disorders (R01-DC008871)
Intellectual and Developmental Disabilities Research Center
National Institutes of Health (R01MH107506, R01HD093776)
Received: 18 February 2020
Accepted: 10 December 2020
First Online: 23 January 2021
Ethics approval and consent to participate
: Ethics approval was obtained from The Children’s Hospital of Philadelphia Institutional Review Board and consent to participate was obtained from parents of all study participants.
: Not applicable
: TR discloses consulting/advisory board positions with CTF, Ricoh, Prism Clinical Imaging, AveXis, Spago Nanomedicine, and Acadia Pharmaceuticals. TR and JCE disclose IP related to the use of MEG as a biomarker for ASD. No other authors declare any financial disclosures.